NCT01790568View on ClinicalTrials.gov

Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

January 1, 2017

Study Completion Date

October 31, 2017

Conditions
Graft vs Host DiseaseHematologic NeoplasmsNon-Neoplastic Hematologic and Lymphocytic Disorder
Interventions
DRUG

Vorinostat

administered at a dose of 100 mg orally, twice daily starting on day -10 in order to achieve steady-state prior to beginning the conditioning chemotherapy, and continued after transplant (day 0) until day +100.

DRUG

Tacrolimus

DRUG

Methotrexate

Trial Locations (1)

48109

University of Michigan Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT01790568 - Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant | Biotech Hunter | Biotech Hunter